Komunikaty prasowe są wydawane przez FUJIFILM Corporation w Japonii.
Fujifilm nie gwarantuje, że produkty w tych komunikatach prasowych są dostępne w sprzedaży we wszystkich krajach i regionach.
Należy pamiętać, że zawartość tej witryny internetowej jest aktualna w dniu ogłoszenia prasowego i może ulec zmianie bez wcześniejszego powiadomienia. Informacje w każdym komunikacie, w tym o dostępności produktu, specyfikacji, cenach i kontaktach, są ważne w momencie publikacji.
- Sty. 6, 2023
- FUJIFILM Cellular Dynamics Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies
- Gru. 13, 2022
- Fujifilm to Build an Advanced Semiconductor Materials Manufacturing Facility in South Korea
- Lis. 22, 2022
- Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility
- Paź. 19, 2022
- Fujifilm develops “FUJINON HZK25-1000mm”
- Paź. 6, 2022
- Fujifilm to establish its first Bio-CDMO site in Japan
- Paź. 3, 2022
- Fujifilm to establish a local subsidiary in South Korea to accelerate business growth of cell culture media
- Wrz. 8, 2022
- Fujifilm announces a strategic investment in a new production facility in Kumamoto Japan to support the fast-growing semiconductor industry
- Lip. 6, 2022
- Fujifilm launches FUJIFILM PROJECTOR Z6000
- Lip. 1, 2022
- Fujifilm launches world’s first mobile app “FUJIFILM Prescale Mobile” that quantifies pressure based on color development on pressure measurement film
- Cze. 30, 2022
- Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services
- Cze. 8, 2022
- Fujifilm Acquires European Inkjet System Integrator UNIGRAPHICA to Expand Inkjet Integration Business Globally
- Kw. 5, 2022
- Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Mar. 29, 2022
- Fujifilm Completes Acquisition of Shenandoah Biotechnology
- Mar. 28, 2022
- Fujifilm Invests in a new manufacturing facility for inkjet pigment dispersions in the U.S.
- Mar. 23, 2022
- Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins
- Sty. 26, 2022
- Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Gru. 8, 2021
- Fujifilm Kicks Off Operations at its New, State-of-the-Art Cell Culture Media Manufacturing Facility in Europe
- Gru. 1, 2021
- FUJIFILM Irvine Scientific Establishes a Bioprocessing Innovation and Collaboration Center in China (FUJIFILM Irvine Scientific)
- Paź. 20, 2021
- Fujifilm launches 4K-compatible broadcast lens with 107× zoom “FUJINON UA107x8.4BESM”
- Wrz. 30, 2021
- Fujifilm agrees on core terms with Australian regenerative medicine venture Cynata to manufacture Cynata’s iPS cell-derived regenerative medicine products